What is the ROCE (Return on Capital Employed) of Inhibrx this year?
The ROCE of Inhibrx is -5.04 undefined this year.
Inhibrx ROCE 2024
Inhibrx ROCE
-5.04
Ticker
INBX
ISIN
US45720L1070
WKN
A2PQMH
In 2024, Inhibrx's return on capital employed (ROCE) was -5.04, a 126.75% increase from the -2.22 ROCE in the previous year.
Inhibrx Aktienanalyse
What does Inhibrx do?
Inhibrx Inc is a biopharmaceutical company specializing in the development and commercialization of therapeutic antibodies. The company was founded in 2011 and is headquartered in La Jolla, California. Inhibrx's business model is based on the research and development of innovative antibodies targeting various diseases such as cancer, inflammation, autoimmune diseases, and infectious diseases. The company utilizes proprietary technologies and platforms to produce a wide range of antibodies that specifically target and block key proteins in the body. Inhibrx is divided into two business segments: the clinical development department and the research and development department. The clinical development department is responsible for conducting clinical trials of the company's antibodies. The research and development department is responsible for the development and refinement of new antibody platforms and technologies. Inhibrx has a number of products in the pipeline, including IRX-2, an antibody developed for the treatment of patients with solid tumor diseases. IRX-2 targets the PD-L1 and PD-L2 proteins, which are overexpressed by many cancer cells and help tumor cells evade immune defenses. In clinical studies, IRX-2 has shown significant reduction in tumor volume in many patients. Another promising product from Inhibrx is IRX-6, an antibody developed for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis. IRX-6 targets the protein BAFF, which plays a key role in the activation of immune cells. Inhibrx has also partnered with pharmaceutical company Celgene Corporation to develop new cancer therapies. As part of the partnership, Inhibrx will utilize its proprietary antibody platforms and technologies to identify and develop new cancer therapies. Inhibrx has an excellent reputation in the industry and has been recognized multiple times for its innovative approaches and technologies. The company has secured a place among the leading biopharmaceutical companies and is expected to continue playing a significant role in the development of new therapies. Inhibrx ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Inhibrx's Return on Capital Employed (ROCE)
Inhibrx's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Inhibrx's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Inhibrx's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Inhibrx’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Inhibrx stock
How has the ROCE (Return on Capital Employed) of Inhibrx developed compared to the previous year?
The ROCE of Inhibrx has increased by 126.75% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Inhibrx?
A high Return on Capital Employed (ROCE) indicates that Inhibrx has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Inhibrx?
A low ROCE (Return on Capital Employed) can indicate that Inhibrx has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Inhibrx impact the company?
An increase in the ROCE of Inhibrx can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Inhibrx affect the company?
A decrease in ROCE of Inhibrx can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Inhibrx?
Some factors that can affect Inhibrx's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Inhibrx so important for investors?
The ROCE of Inhibrx is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Inhibrx take to improve the ROCE?
To improve the ROCE, Inhibrx can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Inhibrx pay?
Over the past 12 months, Inhibrx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibrx is expected to pay a dividend of 0 USD.
What is the dividend yield of Inhibrx?
The current dividend yield of Inhibrx is .
When does Inhibrx pay dividends?
Inhibrx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Inhibrx?
Inhibrx paid dividends every year for the past 0 years.
What is the dividend of Inhibrx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Inhibrx located?
Inhibrx is assigned to the 'Health' sector.
Wann musste ich die Aktien von Inhibrx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Inhibrx from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.
When did Inhibrx pay the last dividend?
The last dividend was paid out on 11/9/2024.
What was the dividend of Inhibrx in the year 2023?
In the year 2023, Inhibrx distributed 0 USD as dividends.
In which currency does Inhibrx pay out the dividend?
The dividends of Inhibrx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Inhibrx
Our stock analysis for Inhibrx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibrx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
